share_log

中金:维持IMAX CHINA(01970)“跑赢行业”评级 目标价降至7.7港元

CICC: Maintaining IMAX CHINA's (01970) “Outperforming the Industry” Rating Target Price Reduced to HK$7.7

Zhitong Finance ·  Feb 28 01:55

The Zhitong Finance App learned that CICC released a research report stating that it maintained the IMAX CHINA (01970) “outperforming the industry” rating and lowered the 2024 and 2025 non-IFRS net profit forecast by 23.5%/22.1% to US$3228/35.17 million, considering the slowdown in system installation. The target price was reduced by 7.2% to HK$7.7, taking into account adjustments in profit forecasts and abundant reserves for subsequent imported films. The company announced 2023 results: revenue of US$86.98 million, up 18.6% year on year; net profit of US$27.5 million, up 156% year on year; non-IFRS net profit of US$29.83 million, up 141% year on year. The performance was lower than expected, mainly due to lower than expected number of system installations.

The main views of CICC are as follows:

IMAX box office revenue recovered year-on-year in 2023, and the brand effect continued to extend to domestic films.

The company's 2023 content solutions revenue was $25.52 million, up 71.2% year over year. According to the announcement and ARN, IMAX China's box office in 2023 was US$298 million, an increase of 83.3% year over year, which is basically in line with the national box office growth rate of 83.4%. The bank believes that the company's box office revenue has clearly recovered year over year under the steady recovery of the film industry, and that IMAX domestic films have performed relatively well, such as “Wandering Earth 2” and “Fengshen 1.” The brand effect continues to extend to domestic films, but the preference for imported films is still relatively weak, and the performance is relatively lackluster. Meanwhile, due to the increase in the share of content solution revenue (29.4% in 2023, up 9.1ppt year on year), the company's overall gross margin increased 8.3 ppt to 62.7% year on year, further strengthening its asset-light attributes.

The domestic cinema terminal is still recovering, and the company's system installation pace is relatively stable.

In 2023, the company's revenue from technology products and services was US$60.9 million, up 4.5% year on year. In 2023, the company installed 13 new cinema systems (10 sets in 2022; 78 sets in 2019); a total of 26 new sets were installed, 13 were closed, and 2 sets were transported, while the division and sales models were 12 sets (1 set of handling) and 14 sets (1 set of handling), respectively, without laser upgrades. At the end of 2023, the company had a total of 774 systems in Greater China. The bank believes that domestic cinemas are still in the recovery stage, and the pace of demand for new or upgraded high-end cinemas may slow down. It is recommended to pay attention to the subsequent progress of box office recovery in the industry and the demand for quality upgrades after the efficiency of cinema-side operations is improved.

The film reserve is rich. Pay attention to the schedule pace and box office performance of subsequent imported films.

According to the announcement and Cat's Eye Pro, imported films to be screened in 2024 include “Dune 2” (scheduled for March 8 in mainland China), “Kung Fu Panda 4” (scheduled for March 22 in mainland China), “Godzilla vs. Kong 2: Rise of the Empire” (scheduled for mainland China on March 29), “Rise of the Planet of the Planet” (scheduled for May 10 in North America), and “Deadpool 3” (scheduled for July 26 in North America). The bank determined that with the scheduled release of more imported films, the company's annual box office revenue may be flexible, and it will continue to pay attention to the pace of system installation and the box office performance of IMAX movies.

Risk warning: There is a liquidity risk that the number of film screenings and system installations is lower than expected, and the transaction volume is low.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment